Novo Nordisk is slashing prices for its diabetes and weight loss drugs Ozempic and Wegovy in India. This move aims to make these treatments...

Novo Nordisk has significantly slashed prices for Ozempic and Wegovy in India, reducing them by 36% and 48% respectively, to enhance patien...

Novo Nordisk's weight-loss drug patents have expired in India. Several generic companies have launched their versions, increasing competiti...

Wegovy and Ozempic ⁠price cuts will be effective January 1 next year, coinciding with the implementation of new, lower prices for the same ...

The Trump administration launched TrumpRx.gov on Thursday (February 5, 2026), a website designed to help Americans purchase prescription dr...

NVO Novo Nordisk stock today: Novo Nordisk shares tumbled after the drugmaker forecast a sales and profit drop for 2026. This outlook comes...

Eli Lilly and Novo Nordisk are in a race to dominate India's booming obesity drug market. They are using aggressive marketing, doctor outre...

Novo Nordisk has launched Ozempic in India at a competitive price, aiming to capture a significant share of the growing weight-loss market....

Novo Nordisk has slashed Wegovy prices in India by nearly 40 percent. This move has dramatically increased sales volume by 70 percent in No...

Danish drugmaker Novo Nordisk is set to launch its popular diabetes drug Ozempic in India this month. This move aims to capture a significa...

Indian drugmakers are adjusting prices for weight-loss injections after Novo Nordisk cut prices for its drug Wegovy. This move is prompting...

Novo Nordisk is offering a new discount on its GLP-1 drugs Ozempic and Wegovy for a short time. The prices are lower for both new and exist...

According to renowned endocrinologist Dr Shashank Joshi, a steep cut in the prices of Wegovy will help improve access and affordability. “B...

Novo and Lilly are locked in a race for dominance in India, a key battleground for weight-loss treatments in the booming global market, whi...

Novo Nordisk warned of ongoing competition from copycat versions of its obesity drug Wegovy and signaled possible layoffs due to slowing sa...

Hims stock took a major hit after Novo Nordisk suddenly ended their Wegovy partnership, causing shares to drop over 20% in a single day. Th...

In a groundbreaking achievement, Novo Nordisk's obesity medication Wegovy has not only demonstrated its efficacy in substantial weight loss...